Get started
AUROBINDO PHARMA LTD.AUROBINDO PHARMA LTD.AUROBINDO PHARMA LTD.

AUROBINDO PHARMA LTD.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

AUROPHARMA chart


Full chart

AUROPHARMA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪733.15 B‬ INR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
20.45
Basic EPS (TTM)
61.25 INR
Net income (FY)
‪31.73 B‬ INR
Revenue (FY)
‪287.25 B‬ INR
Shares float
‪274.12 M‬
Beta (1Y)
0.65

Employees


Employees (FY)
‪37.6 K‬
Change (1Y)
‪+4.18 K‬ +12.52%
Revenue / Employee (1Y)
‪7.64 M‬ INR
Net income / Employee (1Y)
‪843.96 K‬ INR

About AUROBINDO PHARMA LTD


Sector
Health Technology
CEO
Kambam Nithyananda Reddy
Headquarters
Hyderabad
Website
aurobindo.com
Founded
1986
ISIN
INE406A01037
FIGI
BBG000BMFT44
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. It operates under the following geographical segments: India, USA, Europe, and Rest of the World. Its portfolio includes antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterological, anti-allergies, and anti-diabetics. The company was founded by Penaka Venkata Ramprasad Reddy and Kambam Nithyananda Reddy on December 26, 1986 and is headquartered in Hyderabad, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AUROPHARMA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AUROPHARMA is 1,255.95 INR — it has increased by 1.00% in the past 24 hours. Watch AUROBINDO PHARMA LTD. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange AUROBINDO PHARMA LTD. stocks are traded under the ticker AUROPHARMA.
AUROPHARMA stock has risen by 5.28% compared to the previous week, the month change is a 1.52% rise, over the last year AUROBINDO PHARMA LTD. has showed a 18.05% increase.
We've gathered analysts' opinions on AUROBINDO PHARMA LTD. future price: according to them, AUROPHARMA price has a max estimate of 1,930.00 INR and a min estimate of 1,225.00 INR. Watch AUROPHARMA chart and read a more detailed AUROBINDO PHARMA LTD. stock forecast: see what analysts think of AUROBINDO PHARMA LTD. and suggest that you do with its stocks.
AUROPHARMA reached its all-time high on Sep 13, 2024 with the price of 1,592.55 INR, and its all-time low was 10.15 INR and was reached on Nov 6, 2008. View more price dynamics on AUROPHARMA chart.
See other stocks reaching their highest and lowest prices.
AUROPHARMA stock is 2.24% volatile and has beta coefficient of 0.65. Track AUROBINDO PHARMA LTD. stock price on the chart and check out the list of the most volatile stocks — is AUROBINDO PHARMA LTD. there?
Today AUROBINDO PHARMA LTD. has the market capitalization of ‪733.15 B‬, it has increased by 1.16% over the last week.
Yes, you can track AUROBINDO PHARMA LTD. financials in yearly and quarterly reports right on TradingView.
AUROBINDO PHARMA LTD. is going to release the next earnings report on Feb 14, 2025. Keep track of upcoming events with our Earnings Calendar.
AUROPHARMA earnings for the last quarter are 14.00 INR per share, whereas the estimation was 16.05 INR resulting in a −12.75% surprise. The estimated earnings for the next quarter are 15.42 INR per share. See more details about AUROBINDO PHARMA LTD. earnings.
AUROBINDO PHARMA LTD. revenue for the last quarter amounts to ‪77.96 B‬ INR, despite the estimated figure of ‪77.88 B‬ INR. In the next quarter, revenue is expected to reach ‪76.70 B‬ INR.
AUROPHARMA net income for the last quarter is ‪8.17 B‬ INR, while the quarter before that showed ‪9.19 B‬ INR of net income which accounts for −11.08% change. Track more AUROBINDO PHARMA LTD. financial stats to get the full picture.
As of Dec 26, 2024, the company has ‪37.60 K‬ employees. See our rating of the largest employees — is AUROBINDO PHARMA LTD. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AUROBINDO PHARMA LTD. EBITDA is ‪64.74 B‬ INR, and current EBITDA margin is 19.89%. See more stats in AUROBINDO PHARMA LTD. financial statements.
Like other stocks, AUROPHARMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AUROBINDO PHARMA LTD. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AUROBINDO PHARMA LTD. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AUROBINDO PHARMA LTD. stock shows the buy signal. See more of AUROBINDO PHARMA LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.